Full-Time

Senior Manager

Operational Risk Management

Posted on 9/9/2025

Deadline 10/15/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$139.3k - $180.6k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Franklin Township, NJ, USA + 3 more

More locations: Princeton, NJ, USA | Devens, MA, USA | Dublin, Ireland

Hybrid

This position is hybrid, requiring some in-office presence.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis
Requirements
  • Bachelor's degree in pharmaceutical sciences, engineering, biology, or other related discipline or equivalent combination of education and experience. Master’s degree a plus. R&D experience a plus.
  • A minimum of 8 years of biopharmaceutical/pharmaceutical industry experience with at least 2 years in risk management leadership role.
  • Expertise in GMP compliance, Quality System and global GMP regulations with different QRM methodologies in GXP areas (GMP, GDP, GLP, Medical Devices, Cell Therapy, GCP & GVP).
  • Must have strong knowledge and experience with Quality Risk Management, strong demonstrated experience in conducting risk assessments
  • Experience in capability building in general and in Quality Risk Management
  • Experience in authoring and reviewing various documentations such as SOPs, WIS, presentations and training material
  • Demonstrated ability to work in a matrixed organization with a range of technically, culturally, and geographically diverse teams and to influence areas not under direct control to achieve objectives and effectively communicate challenging goals and objectives.
  • Excellent analytical and problem-solving skills, with the ability to identify and mitigate risks effectively
  • Enterprise mindset to be able to think and act across functions and divisions.
  • Ability to work in a fast-paced and dynamic environment, managing multiple priorities simultaneously.
  • Strong leadership and project management skills, with the ability to lead cross-functional teams.
  • Expert-level knowledge and experience using data to drive understanding, decisions, and recommendations Excellent communication and interpersonal skills, with the ability to collaborate effectively with stakeholders at all levels.
  • Demonstrates innovation, flexibility, open-mindedness, and adaptability to meet objectives in a rapidly changing environment with shifting priorities.
  • Strong communication, collaboration, negotiation, problem solving and interpersonal skills. Has a proven track record of working across regulator/industry boundaries to find common solutions and drive positive impact and benefits for patients.
  • Ability to travel 10-20 % as needed.
Responsibilities
  • Proactively identify needs for QRM specific capability building: This entails supporting the development and management of a structured approach to continue and enhance building the Quality Risk Management (QRM) skills and abilities within BMS.
  • Provide guidance and support enterprise wide for enhancing risk management capabilities and QRM process elements in partnership with the Director Quality Risk Management.
  • Provide QRM content and expertise in different training modalities Enterprise-Wide through various formats and channels, ensuring accessibility for employees throughout the entire company. Modalities may include online courses, workshops, webinars, printed materials, interactive session and a well developed up to date repository.
  • Train and support business on risk management tools and methodology, offering guidance on policies, SOPs, and internal control frameworks.
  • Support QRM program: process design, deployment, maintenance, monitoring and improvement of QRM procedures and methodologies (tools) via collaboration and by authoring and/or reviewing procedures.
  • Support GXP Phase Appropriate QRM Content in Processes, procedures and learning material in collaboration with the business by tailored approaches adhering to the specific regulatory requirements and standards applicable to each phase.
  • Build formal Certification Program for employees to achieve certain standards or levels of proficiency in QRM include designing the certification criteria, managing assessments or evaluations, and awarding certifications to qualified individuals and support the program.
  • Co-Chair the Facilitator Best Practice Sharing Forum: This element focuses on creating and maintaining a platform or forum where facilitators involved in the QRM processes can share best practices, insights, and experiences. The forum will serve as a collaborative space to enhance the skills of facilitators and to ensure consistency and quality in QRM practices across the organization.
  • Provide leadership, coaching, and training for PLs and COP and facilitators including both the technical processes and the behaviors necessary to optimize QRM process execution.
  • Provide PEARL trainings and follow-up with identified teams and prepare reports regularly or on demand such as for Quality and Governance Councils.
  • Collaborates on digital QRM with key stakeholders. Support the testing and roll out of IT systems supporting QRM processes and data analytics.
  • Support process monitoring/adoption and GxP risk profiles through data collection, analysis, trending and reporting of QRM dashboards in collaboration with I&T.
  • Stakeholder Partnering and Engagement: Support together with the Associate Director Risk Management the partnership with teams across BMS for stakeholder-oriented incorporation/improvement of QRM principles and appropriate risk-based approaches into the business processes of the Quality Management System enterprise-wide.
  • Support the Director, External Engagement Insights Integrator in leading PEARL process and teams and by this risk identification and continuous improvement of external engagement and regulatory intelligence.
  • Support the Director External Engagement in driving BMS external involvement in key focused areas with highest impact to the company, its products and patients, through building external networks with industry and regulators, and risk-based and continuous improvement mindset.
  • Foster a culture of risk awareness, risk informed decision making and proactive risk management throughout the organization and by this increase QRM maturity.
  • Support QRM Communication for different meetings and purposes.
  • Business support: Support process monitoring through data collection, analysis, trending and reporting of QRM dashboards in collaboration with I&T. Provides guidance on QRM methodologies and can support the business by conducting facilitation of risk assessments.
  • Stay updated with industry best practices and regulatory requirements related to QRM, regulatory trends and regulatory intelligence, communicate within BMS and adapt internal processes effectively.
  • Collaborate with internal and external stakeholders to ensure alignment and compliance with QRM processes.
  • Monitor and evaluate the effectiveness of QRM initiatives, and recommend improvements as needed. Support site and function teams during regulatory inspections or audits, which may include direct interface with inspectors/auditors and writing/reviewing responses.
Desired Qualifications
  • Master’s degree a plus.
  • R&D experience a plus.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth Portfolio averages 16% YoY growth over two years per Q1 2026 results.
  • Eliquis on Cost Plus Drugs at $345/30-day expands access from April 27.
  • FoundationOne CDx expansion detects MTAP deletion for targeted oncology therapy.

What critics are saying

  • Eliquis generics from Apotex erode $14.4B sales post-2026 patent expiry.
  • Revlimid sales plunge drives 5.1% revenue drop in next 12 months.
  • FDA revoked Krazati approval May 5, 2026, after failed NSCLC PFS trial.

What makes Bristol Myers Squibb unique

  • Mezigdomide plus carfilzomib beats Kd in SUCCESSOR-2 Phase 3 PFS for RRMM.
  • Sotyktu gains EU approval May 2026 for psoriatic arthritis post-POETYK trials.
  • Cobenfy switch study shows 8-week PANSS stability from atypicals in schizophrenia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

360Dx
Apr 21st, 2026
In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion.

In expanded BMS collaboration, Foundation Medicine to develop CDx to detect MTAP deletion. NEW YORK - Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to develop FoundationOne CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. Get the full story with 360dx Premium. Only $95 for the first 90 days. Full site access Interest-based email alerts Premium Access - Trial Offer $95.00 for 3 month

Yahoo Finance
Apr 13th, 2026
Bristol Myers Squibb: 4.2% dividend yield and stable revenue at bargain valuation

Bristol Myers Squibb presents an attractive value investment in the pharmaceutical sector, with a forward price-to-earnings ratio of 9.5, significantly lower than competitors Johnson & Johnson (21) and Merck (24). The company offers a 4.2% dividend yield and has increased payouts for 17 consecutive years. Bristol reported $48.2 billion in revenue for 2025, with 2026 guidance between $46 billion and $47.5 billion, demonstrating consistency despite modest decline. However, the favourable valuation reflects investor concerns about slowing legacy portfolio revenue, which fell from $25.7 billion in 2024 to $21.8 billion in 2025. Key challenges include an upcoming patent cliff for Eliquis, its blood thinner generating $14.4 billion in 2025 sales, and the $1.5 billion acquisition of Orbital Therapeutics whilst carrying over $47 billion in debt.

Yahoo Finance
Apr 10th, 2026
Bristol Myers' Cobenfy hits $155M in first year, outpacing rival schizophrenia treatments

Bristol Myers Squibb's schizophrenia drug Cobenfy generated $155 million in sales during 2025, outpacing comparable treatments in its first year following FDA approval in September 2024. The medication represents the first new pharmacological approach to treating schizophrenia in decades. Recent phase II data presented at the Schizophrenia International Research Society Annual Congress showed adults with schizophrenia remained stable after switching to Cobenfy monotherapy over eight weeks, with low discontinuation rates and no dropouts due to lack of efficacy. Bristol Myers is pursuing label expansions across multiple indications, with ongoing phase III studies in Alzheimer's disease psychosis, agitation, cognitive impairment, bipolar I disorder and paediatric irritability associated with autism. The company expects Cobenfy to become a significant growth driver as legacy drugs face generic competition.

Buzzword News
Mar 30th, 2026
Bristol Myers Squibb adding 3 medications on TrumpRx.

Bristol Myers Squibb adding 3 medications on TrumpRx. Mar 30, 2026 - 14:01 EXCLUSIVE: Bristol Myers Squibb is launching three medications on TrumpRx.gov on Monday, FOX Business has learned. The three prescription drugs will each be offered at deep discounts that range from 40% to 90% off the retail price. The Princeton, New Jersey-based company's drug Sotyktu retails for $7,135.55 and will be offered through TrumpRx.gov for $743. That represents a 90% discount off what patients have been paying. Sotyktu treats adults with moderate-to-severe plaque psoriasis. Zeposia, which treats relapsing forms of multiple sclerosis, will be added at a discount of between 88% and 90%. The weekly injection to treat moderate-to-severe rheumatoid arthritis, Orencia SC, will be reduced by 40% from the retail price. A White House official said this is the latest big pharma company to offer reduced prices after the tariff pressure from President Donald Trump. The talks with pharmaceutical companies continue to be successful, with more medications added to the government website. Bristol Myers' additions come weeks after FOX Business reported that Amgen and GSK were added to the list of prescription drug manufacturers offering discounts on the government website. Amgen offers medications on the website that cut 80% off the retail price. Amjevita has an original price of $1,484, but will be available on TrumpRx.gov for $299. The medication treats rheumatoid arthritis, psoriasis and ulcerative colitis. Amgen also lists Aimovig and Repatha for discounts of 62%. GSK discounts Incruse at 55% off the retail price. The drug treats COPD and will be listed at $159.20. GSK lists Arnuity, Relenza and Anoro at discounts ranging from 10% to 51%. The White House is pushing ahead with announcements to TrumpRx.gov as Americans look for ways to cut medical costs. Under the Biden administration, Bureau of Labor Statistics data shows, prescription drug costs increased 10.4% from January 2021 to January 2025. Under the Trump administration, prescription drug prices increased 0.2% from January 2025 through the latest data from February 2026.

Insider Monkey
Mar 30th, 2026
Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment.

Bristol-Myers Squibb gets FDA approval for Hodgkin's Lymphoma treatment. Published on March 30, 2026 at 2:07 am by sultan khalid in news. Bristol-Myers Squibb Company (NYSE:BMY) is included among the 15 Large Cap Stocks with Highest Dividends. Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company (NYSE:BMY) announced on March 20 that the U.S. Food and Drug Administration had approved the company's combination treatment for adults and adolescents aged 12 and older with previously untreated stage III or IV classical Hodgkin's lymphoma. The antitumor therapy, called Opdivo, had previously received the green light to treat various advanced or metastatic cancers, including melanoma, non-small cell lung cancer, and kidney cancer. The regulatory authority's decision is based on a late-stage study of 994 patients, which demonstrated that the treatment significantly improved progression-free survival compared with brentuximab vedotin. Hodgkin's lymphoma, also known as Hodgkin's disease, is the most common form of cancer in patients aged 15 to 19. It starts in white blood cells, which are part of the body's immune system, a cancer that starts in white blood cells. Monica Shaw, MD, Senior Vice President of Oncology Commercialization at Bristol-Myers Squibb Company (NYSE:BMY), stated: "These approvals represent a defining moment for people living with classical Hodgkin Lymphoma. In the U.S., we are particularly proud that Opdivo in combination with AVD now stands as an immunotherapy combination available for adults and pediatric patients, ages 12 and older, with previously untreated advanced disease. Concurrently, in the EU, Opdivo in combination with brentuximab vedotin has also achieved a milestone as the first immunotherapy combination for certain relapsed or refractory patients. These milestones reflect our continued commitment to advancing science that meaningfully improves the lives of patients and families worldwide." While we acknowledge the risk and potential of BMY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

INACTIVE